Table 2 Clinical information (diagnosis and pathological) of KHP Bladder Cancer Biobank from April 2017–June 2019
From: Cohort profile: King’s Health Partners bladder cancer biobank
Clinical variable | Consented (n = 531) | % |
|---|---|---|
Diagnosis | ||
New | 342 | 64.4 |
Recurrence | 189 | 35.6 |
Histology | ||
Urothelial Cell Carcinoma | 308 | 58.0 |
Papillary Urothelial Cell Carcinoma | 165 | 31.1 |
Squamous Cell Carcinoma | 17 | 3.2 |
Adenocarcinoma | 7 | 1.3 |
Micropapillary variant | 7 | 1.3 |
Plasmacytoid variant | 3 | 0.6 |
Paraganglioma | 4 | 0.8 |
Papilloma | 1 | 0.2 |
Small cell carcinoma | 3 | 0.6 |
Sarcomatoid | 2 | 0.4 |
Unknown | 8 | 1.5 |
Grade | ||
G1 | 38 | 7.2 |
G2 | 125 | 23.5 |
G3 | 329 | 62.0 |
Unknown | 39 | 7.3 |
T stage | ||
Ta/ Tis | 193 | 36.3 |
T1 | 133 | 25.0 |
T2 | 106 | 20.0 |
T3 | 65 | 12.2 |
T4 | 14 | 2.6 |
Unknown | 20 | 3.8 |
N stage | ||
N0 | 485 | 91.3 |
N1 | 24 | 4.5 |
N2 | 22 | 4.1 |
M stage | ||
M0 | 502 | 94.5 |
M1 | 29 | 5.5 |
Lymphovascular invasion | ||
Yes | 42 | 7.9 |
No | 489 | 92.1 |
TURBT | ||
Yes | 428 | 80.6 |
No | 103 | 19.4 |
Surgery | ||
Yes | 261 | 49.2 |
No | 270 | 50.8 |
Chemotherapy | ||
Neoadjuvant | 37 | 7.0 |
Adjuvant | 30 | 5.6 |
Chemotherapy | 20 | 3.8 |
Palliative | 6 | 1.1 |
Neoadjuvant and adjuvant | 2 | 0.4 |
None | 436 | 82.1 |
Radiotherapy | ||
Yes | 47 | 8.9 |
No | 484 | 91.1 |
Intravesical Therapy | 0.0 | |
Yes | 180 | 33.9 |
Di Stasi | 76 | 14,3 |
BCG | 62 | 11.7 |
Mitomycin | 33 | 6.2 |
BCG and mitomycin in different occasions | 7 | 1.3 |
Di Stasi and mitomycin in different occasions | 1 | 0.2 |
Other | 1 | 0.2 |
No | 351 | 66.1 |
Intravesical Therapy Failure | ||
Yes | 35 | 6.6 |
Poorly tolerated | 10 | 1.9 |
No | 6 | 1.1 |
Unknown | 129 | 24.3 |
Not applicable | 351 | 66.1 |
Laser ablation | ||
Yes | 9 | 1.7 |
No | 522 | 98.3 |
Immunotherapy | ||
Yes | 17 | 3.2 |
No | 514 | 96.8 |